6,000 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Knott David M Jr

Knott David M Jr bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 6,000 shares of the company’s stock, valued at approximately $626,000.

Several other large investors also recently made changes to their positions in AXSM. Caitong International Asset Management Co. Ltd acquired a new position in Axsome Therapeutics in the 1st quarter worth $25,000. Quantbot Technologies LP acquired a new position in shares of Axsome Therapeutics during the first quarter worth about $31,000. AlphaQuest LLC bought a new position in shares of Axsome Therapeutics during the first quarter worth about $38,000. Neo Ivy Capital Management bought a new position in shares of Axsome Therapeutics during the first quarter worth about $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Axsome Therapeutics in the 1st quarter valued at approximately $47,000. Institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AXSM. HC Wainwright raised their price target on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Guggenheim boosted their price objective on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. B. Riley assumed coverage on shares of Axsome Therapeutics in a research note on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $154.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $179.88.

Insiders Place Their Bets

In other news, Director Roger Jeffs sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $121.60, for a total value of $2,432,000.00. Following the completion of the sale, the director directly owned 90,974 shares of the company’s stock, valued at $11,062,438.40. This trade represents a 18.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Mark L. Jacobson sold 45,783 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $114.48, for a total value of $5,241,237.84. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 407,271 shares of company stock valued at $50,640,415 over the last 90 days. 22.30% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $139.69 on Monday. The company has a fifty day moving average price of $126.29 and a two-hundred day moving average price of $114.83. Axsome Therapeutics, Inc. has a one year low of $75.56 and a one year high of $144.15. The stock has a market cap of $7.04 billion, a P/E ratio of -27.55 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The firm had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The business’s revenue was up 63.2% on a year-over-year basis. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.